Aptevo Therapeutics Inc. (APVO) EPS Estimated At $-0.56 as of May, 11

May 3, 2018 - By Joshua Cleveland

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s quarterly earnings will be revealed on May, 11., as reported by Faxor. Analysts predict 16.67 % diference or $-0.56 from the $-0.48 EPS from 2017. The stock decreased 4.57% or $0.2 during the last trading session, reaching $4.18.Aptevo Therapeutics Inc. has volume of 71,271 shares. Since May 3, 2017 APVO has risen 72.19% and is uptrending. The stock outperformed the S&P 500 by 60.64%.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States.The firm is valued at $93.81 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.12.78 is the P/E ratio. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.